F Barlesi
Overview
Explore the profile of F Barlesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
3553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mosele M, Westphalen C, Stenzinger A, Barlesi F, Bayle A, Bieche I, et al.
Ann Oncol
. 2025 Feb;
PMID: 39984357
No abstract available.
2.
Mosele M, Westphalen C, Stenzinger A, Barlesi F, Bayle A, Bieche I, et al.
Ann Oncol
. 2024 Jun;
35(7):588-606.
PMID: 38834388
Background: Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour...
3.
Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, et al.
ESMO Open
. 2024 Apr;
9(5):103004.
PMID: 38653155
Background: Patients with solid organ transplant (SOT) and solid tumors are usually excluded from clinical trials testing immune checkpoint blockers (ICB). As transplant rates are increasing, we aimed to evaluate...
4.
Charton E, Baldini C, Fayet Y, Schultz E, Auroy L, Vallier E, et al.
ESMO Open
. 2023 Aug;
8(4):101610.
PMID: 37536254
Background: Investigation of the disparities in the access to experimental treatment in early-phase clinical trials is lacking. The objective of the EGALICAN-2 study was to identify the factors underpinning such...
5.
Sicard G, Protzenko D, Giacometti S, Barlesi F, Ciccolini J, Fanciullino R
Br J Cancer
. 2023 Jul;
129(9):1373-1382.
PMID: 37524968
Background: Successful immunotherapy is restricted to some cancers only, and combinatorial strategies with other drugs could help to improve their efficacy. Here, we monitor T cells in NSCLC model after...
6.
Rousseau A, Parisi C, Barlesi F
ESMO Open
. 2023 Mar;
8(2):101184.
PMID: 36933320
Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new...
7.
Bayle A, Belcaid L, Aldea M, Vasseur D, Peyraud F, Nicotra C, et al.
Ann Oncol
. 2023 Jan;
34(4):389-396.
PMID: 36709039
Background: Circulating tumor DNA (ctDNA) sequencing is a promising approach for tailoring therapy in patients with cancer. We report hereby the results from a prospective study where we investigated the...
8.
Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R, et al.
Ann Oncol
. 2022 Sep;
33(12):1328-1331.
PMID: 36122799
No abstract available.
9.
Peyraud F, Guegan J, Bodet D, Nafia I, Fontan L, Auzanneau C, et al.
Ann Oncol
. 2022 Jul;
33(10):1041-1051.
PMID: 35850444
Background: The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the systemic approach to cancer treatment. Most patients receiving ICIs, however, do not derive benefits. Therefore, it is crucial to...
10.
Moreno V, Calvo E, Middleton M, Barlesi F, Gaudy-Marqueste C, Italiano A, et al.
Cancer Immunol Immunother
. 2022 May;
71(12):2985-2998.
PMID: 35596791
Background: We evaluated MK-4621, an oligonucleotide that binds and activates retinoic acid-inducible gene I (RIG-I), as monotherapy (NCT03065023) and in combination with the anti-programmed death 1 antibody pembrolizumab (NCT03739138). Patients...